

# IBC Meeting Minutes

## Cleveland Clinic Florida Research and Innovation Center

<b>Date:</b> April 16, 2026	<b>Location:</b> Zoom
<b>IBC Member Attendance:</b>	
<input type="checkbox"/> McDonald, Christine (IBC Chair) <input checked="" type="checkbox"/> Li, Kun <input checked="" type="checkbox"/> Such, Kimberly <input checked="" type="checkbox"/> Champer, Dylan (BSO, Acting Chair) <input checked="" type="checkbox"/> Hajjar, Adeline <input checked="" type="checkbox"/> Judd, Leslie <input checked="" type="checkbox"/> Tavakoli, Sara <input checked="" type="checkbox"/> O'Connor, Christine <input checked="" type="checkbox"/> Doud, Melissa <input checked="" type="checkbox"/> Stolley, Michael	
<i>Guests: Amanda Dragan*, Abby Bifano*, Anna Rietsch *, Anthony Santilli*, Jennifer Veillette*, Nikki Meyer*</i>	
<i>*Cleveland Clinic Main Campus</i>	
<b>Call To Order:</b> 2:37 pm	<b>Adjourn:</b> 2:50 pm

### I. Review of March 19<sup>th</sup>, 2026 Meeting Minutes

<b>Committee Comments:</b> None			
<b>Motion:</b> Approval	<b>For:</b> 7	<b>Against:</b> 0	<b>Abstain:</b> 2

### II. Administrative Business

- a. Committee presented with Subcommittee Review items and personnel additions.
- b. Lab Audits: Members were presented with and informed of Annual Lab Audits and Preliminary Audits occurring during the month of March 2026. No major deficiencies were identified.

### III. Non-Clinical Research:

#### a. New Applications:

<b>Basic Research Application # 1</b>	<b>Protocol ID:</b> Application #1	<b>PI:</b> Nicosia	<b>Biosafety Level:</b> BSL1, BSL2, ABSL1, ABSL2	<b>NIH Cat.:</b> III-D-4-a
<b>Project Titles:</b> Investigations into tumor development in transplant recipients				
<b>Associated Grant Numbers:</b> Non-NIH Funded				

<b>Protocol Summary:</b>					
<ul style="list-style-type: none"> <li>Acquisition of recombinant tissue culture cells for administration <i>in vivo</i></li> </ul>					
<b>Function/Nature of Recombinant Genes to be Expressed:</b>					
<input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input checked="" type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input checked="" type="checkbox"/> Reporters <input type="checkbox"/> Other					
<b>Species of Recombinant Genes to be Expressed:</b>					
<input type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input type="checkbox"/> Viral <input checked="" type="checkbox"/> Other					
<b>Risk Assessment Discussion:</b>			<b>Facilities, Procedures, and Safety Practices Reviewed (Y/N):</b>		
<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
<b>Committee Comments:</b>					
<ul style="list-style-type: none"> <li>Administrative edits</li> </ul>					
<b>PI/Supervisor Training (Y/N):</b>			<b>Handler Training (Y/N):</b>		
<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
<b>Motion:</b>	<b>For:</b>	<b>Against:</b>	<b>Abstain:</b>	<b>Recuse:</b>	<b>Not Present:</b>
Approved with Administrative Revisions	9	0	0	0	0

**b. Amendments:**

<b>Basic Research Amendment # 1</b>	<b>Protocol ID:</b> FLIBC026	<b>PI:</b> Ross	<b>Biosafety Level:</b> BSL-1, BSL-2, BSL-2+, BSL-3, ABSL-2, ABSL-3	<b>NIH Cat.:</b> III-D-3-a, III-D-4- b, III-D-7-b
<b>Project Titles:</b>				
H2 and H5 Influenza Virus Infection and Vaccination				
<b>Associated Grant Numbers:</b>				
Non-NIH Funded				
<b>Summary of Approved Items:</b>				
Propagation of H2N2, H2N3, H5N1 influenza virus and subsequent assessment <i>in vivo</i> vaccinated under FLIBC019, human-derived materials.				
<b>Requested Additions/Changes:</b>				
<ul style="list-style-type: none"> <li>Addition of new influenza strain</li> </ul>				
<b>Function/Nature of Recombinant Genes to be Expressed:</b>				
<input checked="" type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input type="checkbox"/> Other				
<b>Species of Recombinant Genes to be Expressed:</b>				
<input checked="" type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input type="checkbox"/> Viral <input type="checkbox"/> Other				

<b>Risk Assessment Discussion:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		<b>Facilities, Procedures, and Safety Practices Reviewed (Y/N):</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			
<b>Discussion/Required Modifications:</b> <ul style="list-style-type: none"> <li>• Administrative edits</li> <li>•</li> </ul>					
<b>PI/Supervisor Training (Y/N):</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		<b>Handler Training (Y/N):</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			
<b>Motion:</b> Approved with Administrative Revisions	<b>For:</b> 9	<b>Against:</b> 0	<b>Abstain:</b> 0	<b>Recuse:</b> 0	<b>Not Present:</b> 0